Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Group 1: Guselkumab 100 mg q8w	388
Overall Study	STARTED	Group 2: Guselkumab 100 mg q4w	280
Overall Study	STARTED	Group 3: Placebo Followed by Guselkumab	386
Overall Study	Modified Full Analysis Set	Group 1: Guselkumab 100 mg q8w	371
Overall Study	Modified Full Analysis Set	Group 2: Guselkumab 100 mg q4w	273
Overall Study	Modified Full Analysis Set	Group 3: Placebo Followed by Guselkumab	376
Overall Study	COMPLETED	Group 1: Guselkumab 100 mg q8w	370
Overall Study	COMPLETED	Group 2: Guselkumab 100 mg q4w	270
Overall Study	COMPLETED	Group 3: Placebo Followed by Guselkumab	372
Overall Study	NOT COMPLETED	Group 1: Guselkumab 100 mg q8w	18
Overall Study	NOT COMPLETED	Group 2: Guselkumab 100 mg q4w	10
Overall Study	NOT COMPLETED	Group 3: Placebo Followed by Guselkumab	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04882098/flow